Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)
China · Delayed Price · Currency is CNY 21.07
-0.33 (-1.54%)
At close: Jan 30, 2026
SHE:301246 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Jan '21 Jan 1, 2021 |
Operating Revenue | 1,737 | 1,742 | 2,026 | 2,046 | 1,568 | 1,297 |
Other Revenue | 28.69 | 28.69 | 28.87 | 17.73 | 9.44 | 5.57 |
| 1,766 | 1,771 | 2,055 | 2,064 | 1,578 | 1,303 | |
Revenue Growth (YoY) | -2.91% | -13.83% | -0.43% | 30.79% | 21.10% | -17.24% |
Cost of Revenue | 1,583 | 1,590 | 1,814 | 1,622 | 1,051 | 810.16 |
Gross Profit | 182.58 | 180.95 | 240.49 | 442.18 | 526.52 | 492.78 |
Selling, General & Admin | 102.08 | 91.38 | 98.5 | 102.96 | 108.41 | 97.39 |
Research & Development | 73.36 | 59.18 | 68.82 | 64.01 | 48.71 | 44.54 |
Other Operating Expenses | 5.29 | -5.4 | 11.79 | 9.46 | 12.27 | -2.97 |
Operating Expenses | 182.34 | 145.67 | 176.55 | 180.73 | 170.42 | 139.02 |
Operating Income | 0.24 | 35.28 | 63.94 | 261.45 | 356.11 | 353.77 |
Interest Expense | -9.96 | -12 | -13.4 | -3.41 | -2.38 | -15.45 |
Interest & Investment Income | 8.52 | 14.12 | 36.47 | 172.05 | 192.11 | 4.99 |
Currency Exchange Gain (Loss) | 5.63 | 5.63 | 1.11 | 13.64 | -2.62 | -9.24 |
Other Non Operating Income (Expenses) | -6.01 | -1.73 | -8.43 | -3.09 | -1.02 | 1.31 |
EBT Excluding Unusual Items | -1.58 | 41.31 | 79.69 | 440.65 | 542.21 | 335.37 |
Impairment of Goodwill | - | - | - | - | -6.5 | - |
Gain (Loss) on Sale of Investments | 3.39 | 3.82 | 2.86 | - | - | -14.75 |
Gain (Loss) on Sale of Assets | 0.89 | 0.27 | 0.57 | 14.44 | -0.62 | 1.88 |
Asset Writedown | -5.6 | - | - | -1.97 | -0.76 | -9.89 |
Other Unusual Items | 22.41 | 14.3 | 15.44 | 24.85 | 10.72 | -6.99 |
Pretax Income | 19.52 | 59.69 | 98.56 | 477.98 | 545.04 | 305.62 |
Income Tax Expense | 6.14 | 8.23 | 11.39 | 43.18 | 51.19 | 48.44 |
Earnings From Continuing Operations | 13.38 | 51.46 | 87.17 | 434.8 | 493.85 | 257.18 |
Minority Interest in Earnings | 0.85 | 0 | - | - | - | - |
Net Income | 14.22 | 51.47 | 87.17 | 434.8 | 493.85 | 257.18 |
Net Income to Common | 14.22 | 51.47 | 87.17 | 434.8 | 493.85 | 257.18 |
Net Income Growth | -47.34% | -40.96% | -79.95% | -11.96% | 92.02% | -18.20% |
Shares Outstanding (Basic) | 394 | 399 | 388 | 353 | 353 | 352 |
Shares Outstanding (Diluted) | 394 | 399 | 388 | 353 | 353 | 352 |
Shares Change (YoY) | -1.24% | 2.71% | 10.02% | -0.00% | 0.13% | -0.12% |
EPS (Basic) | 0.04 | 0.13 | 0.22 | 1.23 | 1.40 | 0.73 |
EPS (Diluted) | 0.04 | 0.13 | 0.22 | 1.23 | 1.40 | 0.73 |
EPS Growth | -46.68% | -42.52% | -81.78% | -11.96% | 91.78% | -18.10% |
Free Cash Flow | -334.68 | -176.01 | -439.39 | -292.1 | -62.92 | 85.53 |
Free Cash Flow Per Share | -0.85 | -0.44 | -1.13 | -0.83 | -0.18 | 0.24 |
Dividend Per Share | 0.030 | 0.030 | 0.050 | 0.100 | - | - |
Dividend Growth | -40.00% | -40.00% | -50.00% | - | - | - |
Gross Margin | 10.34% | 10.22% | 11.70% | 21.43% | 33.37% | 37.82% |
Operating Margin | 0.01% | 1.99% | 3.11% | 12.67% | 22.57% | 27.15% |
Profit Margin | 0.81% | 2.91% | 4.24% | 21.07% | 31.30% | 19.74% |
Free Cash Flow Margin | -18.96% | -9.94% | -21.38% | -14.15% | -3.99% | 6.57% |
EBITDA | 194.11 | 212.99 | 220.09 | 350.53 | 435.77 | 428.14 |
EBITDA Margin | 10.99% | 12.03% | 10.71% | 16.98% | 27.62% | 32.86% |
D&A For EBITDA | 193.87 | 177.71 | 156.16 | 89.08 | 79.66 | 74.37 |
EBIT | 0.24 | 35.28 | 63.94 | 261.45 | 356.11 | 353.77 |
EBIT Margin | 0.01% | 1.99% | 3.11% | 12.67% | 22.57% | 27.15% |
Effective Tax Rate | 31.48% | 13.79% | 11.56% | 9.03% | 9.39% | 15.85% |
Revenue as Reported | 1,766 | 1,771 | 2,055 | 2,064 | 1,578 | 1,303 |
Advertising Expenses | - | 1.03 | 0.8 | 0.02 | 0.69 | 0.87 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.